The Impact of Dietary Interventions on Metabolic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Comorbid Conditions, Including Obesity and Type 2 Diabetes.

Joanna Michalina Jurek, Katarzyna Zablocka-Sowinska, Helena Clavero Mestres, Leyre Reyes Gutiérrez, Javier Camaron, Teresa Auguet

Journal: Nutrients 2025;17(7):

PMID: 40219014

Plain Language Summary

plain language summary logo

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health issue connected to problems with the immune system and metabolism. Lifestyle and dietary modifications are important for MASLD management, however it is still unclear which diet and lifestyle modifications are the best. This systematic review of 13 RCTs aimed to review various dietary patterns to determine their effects on metabolic outcomes in patients with MASLD, as well as in those with related conditions like obesity and type 2 diabetes.

The findings suggest that certain dietary changes can positively influence metabolic health in individuals with MASLD and its comorbidities. The Mediterranean diet (MD) and intermittent fasting were shown to benefit body weight, body mass index, waist circumference, blood-sugar control and inflammation. There were limited effects on liver function although improved function and stiffness were linked to dietary changes. The lacto-ovo-vegetarian diet and Dietary Approaches to Stop Hypertension diet had additional benefits including blood pressure management.

It was concluded that the MD and intermittent fasting may be of benefit to liver health and anthropometric measures. However, further safety and long-term studies are needed. This study could be used by healthcare professionals to understand that they should prioritise Mediterranean or intermittent fasting dietary models to support weight loss, improve glycaemic control, and lower inflammation in patients with MASLD. The DASH and lacto-ovo-vegetarian diets may offer additional heart health benefits, particularly for patients with high blood pressure.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a public health concern, linked with immune-metabolic dysfunction. While lifestyle and dietary modifications remain the cornerstone of MASLD management, the optimal dietary approach remains uncertain. This systematic review aims to investigate the impact of model dietary patterns on metabolic outcomes in patients with MASLD and evaluate their effects in individuals with coexisting metabolic conditions, such as obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM). To conduct the review, PubMed, Scopus, Google Scholar, Cochrane CENTRAL, and ClinicalTrials.gov databases were searched for Randomized Controlled Trials (RCTs) on the adult population, published between January 2019 and September 2024, following PRISMA principles. The quality of the included RCTs was assessed qualitatively based on study characteristics. The main findings of this review demonstrated that the use of interventions with dietary model based on Mediterranean diet (MED) and intermittent fasting (IF) approaches, such as alternative-day fasting (ADF) and time-restricted feeding regimens (TRF) may have potential in reducing body weight, BMI, and waist circumference, with additional benefits of improving glycemic control and reducing inflammation. The effects on hepatic functions, although limited, may be linked with reduced enzyme activity and liver stiffness. Additionally, the use of lacto-ovo-vegetarian diet (LOV-D) and the Dietary Approaches to Stop Hypertension (DASH) diet may offer additional health benefits, including blood pressure management. This review suggests that MED and IF-based strategies may reduce BW, improve glycemic control, and lower inflammation, with potential benefits for hepatic function. Further long-term studies are needed to confirm these effects and underlying mechanisms, which will allow for the optimization of protocols and ensure their safety in MASLD.

Address: Grup de Recerca GEMMAIR (AGAUR)-Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Mallafré Guasch, 4, 43007 Tarragona, Spain.; The Faculty of Finance and Management, WSB Merito University in Wrocław, 53-609 Wrocław, Poland.; Servei Medicina Interna, Hospital Universitari de Tarragona Joan XXIII, Mallafré Guasch, 4, 43007 Tarragona, Spain.; Grup de Recerca GEMMAIR (AGAUR)-Medicina Aplicada (URV), Departament de Medicina i Cirurgia, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Mallafré Guasch, 4, 43007 Tarragona, Spain.; Servei Medicina Interna, Hospital Universitari de Tarragona Joan XXIII, Mallafré Guasch, 4, 43007 Tarragona, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.